Corcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and Corporate Update and Host Conference Call

Corcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and Corporate Update and Host Conference Call
  
 

MENLO PARK, CA--(Marketwired - Jan 27, 2014) -  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full year 2013 revenue on January 30, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 36540064.

A replay will be available through February 13, 2014 at 1-888-843-7419 from the United States and [phone] internationally. The passcode is 3654 0064.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Korlym, a first generation GR antagonist, is the company's first FDA-approved medication for use in the treatment of patients with Cushing's syndrome. Corcept has a phase 3 trial underway for mifepristone for treatment of the psychotic features of psychotic depression, as well as a portfolio of selective GR antagonists that block the effects of cortisol without blocking the effects of progesterone. It owns extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of disorders. It also holds composition of matter patents for its selective GR antagonists. For more information about Corcept please visit: www.corcept.com

CONTACT: Charles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 Email Contact www.corcept.com